[Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment].
During menopause the essential modifications in haemostatis are an increase in fibrinogen, in PAI and in factor VII, all of which are arterial risk factors. Women who have undergone physical training or polymorphism of factor VII are protected from unfavourable modifications in haemostasis. Hormone replacement therapy tends to correct modifications of arterial risk factors (decrease in fibrinogen and PAI), which is a beneficial effect of treatment. This treatment also induces other changes that are venous risk factors (decrease in antithrombin and protein S) and these constitute an unfavourable treatment effect. The most important variations are associated with conjugated equine oestrogens. The transcutaneous administration of oestrogens is associated with no variations in haemostasis, which seem to have a favourable effect on venous risk but the effect on cardiovascular risk could be ineffective if the fibrinolysis parameters will be predominant.
Conard
J
J
Service d'Hématologie Biologique, Hôtel-Dieu, Paris, France.
D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000235:genetics / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D015444:Exercise; D005167:Factor VII / Q000235:genetics; D005260:Female; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008593:Menopause; D012307:Risk Factors
D005167:Factor VII